{"name":"Io Therapeutics","slug":"io-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE54YTd6U0Z6bkhSVmR3cEFEd2lESjRaQjRpZU1paTR6T1dmQjVJTFJETkd3UXNSaGdja1NQbDFocDVaZHV0M0NyRThZT2REM1RWYldvMTJQanRiYS00NzEzVTB1Njl1bEpOQ19ST0x6cmUzTlRKZ2pOZDQtNnI?oc=5","date":"2026-03-31","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE53TnBMSWhDRW1UcU9RamxTSjNLRUhpVGY0T0c4RlRSMl8yQ25Tc2lFMXM5NzRSb1hTRTZ5ZkExdDdXb3FHYzhSdEhnNGlRU2tCUmFJem1MZ2tzUmtXNG43aEpKcXJqME9NUlJpdVg5aGZsZ2lzN3ZyT05VLVI0TUE?oc=5","date":"2026-03-30","type":"pipeline","source":"CryptoRank","summary":"Regeneron Pharmaceuticals Tokenized Stock (Ondo) - CryptoRank","headline":"Regeneron Pharmaceuticals Tokenized Stock (Ondo)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQZ1FuVy1DX1dGMjg0eUFwOHJTNE1PTDU1eUdGUWU3eHVGOHZqcmpxZ1l0TEpjMTh5TE0xdERjbDB5SFdQRUNyUU1aNFJGUDk1VE5KdEJtTXJlX3FxQnQyTktFUDJDZFU4TTFzRVhHbWRsM2dsazhwZjV1ZFZ6dW8ya25wUHMycjh2TUZISlRBSUtHNTVlZFZoeDd4eGpNU3BkOEQ2NHJhekdWSEZXR2Q5RkhrZw?oc=5","date":"2026-03-25","type":"pipeline","source":"GuruFocus","summary":"IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus","headline":"IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBaeGkyenN3UjVHVXpHZXB3dXV0OWp4Z250ZElNX1dKWGdhRW5VZFJLLXhLZENYUGZGS1dReUVYMlViWXkxWFpNSy1pM0dlelJkQzIw?oc=5","date":"2026-01-21","type":"regulatory","source":"FirstWord Pharma","summary":"Biopharma Bites: Insilico snags an NLRP3, FDA's manufacturing pilot, plus more from Lisata and Cylembio - FirstWord Pharma","headline":"Biopharma Bites: Insilico snags an NLRP3, FDA's manufacturing pilot, plus more from Lisata and Cylembio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQQlBUV3RaaC1ZZk9wNTZzWHRmZXNfSFByX3RWMkpCYjdzdmJlamlpeTNKczJ4OG9kZU9GSHVIbEdmQVMtRk9zM3NaX2t1ZzV1c0s1c2hEckpWdWNkcGpYZEpSZnpUMDF4U3VPYUo2djA3djZoMXdPOHpHVVZFb2dWR29YMGNJVzJ4aVE?oc=5","date":"2025-12-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Takeda and Innovent fulfil close conditions for ADC and IO therapies - Pharmaceutical Technology","headline":"Takeda and Innovent fulfil close conditions for ADC and IO therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxONGttTWd4UzA1dGpVX3hXM2J1Y0ljb1BEeWl6cEVsbEQzUnktU05INTdzZXBSN1U1N0JScHl3X0NZbFM5UXRudDNJV0FnQTVCSm1hLURDZ2ZUUTRRWWpCUE5oaENjdnZDWlFjNGMxOFFKY3YwYmFZQTBpSnRHeDVUdHZmVjJFbVpSSmEybl8tZXlxV0hSWVZLUmMzMG04eGs1NGVzNE1NWDQ?oc=5","date":"2025-10-22","type":"deal","source":"BioWorld News","summary":"Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets - BioWorld News","headline":"Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOd1RvaW55T0ZqRFRQSVdCblFHRXNjM1Zjdl9qcFlOVnRqTXRHeDhBcVZxSGRWSGlQSkoxWVo4Nm9qUXJRUzlNZ2hRRUJ1LWJLS2NjMldwTHdGdUZWaGZRcEZVbkxXM0g3OE4yMFlyLXZaM1ZjTjVhVWN6cEFqeVQ0elpHeDhGRzBxV1FlNFhuRUs1c3JMNWpEUVlEa21fR0t4MjlLWHBkQ3dZYU8zSHM0SWdjVWJ6MEdyand5and3SVZtcHl3dWs2c1MwOVQ3eEUyUmw3VVBjQmY1dm8?oc=5","date":"2025-08-12","type":"trial","source":"Reuters","summary":"IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters","headline":"IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE8tNm9uclRjeTJjcEpUbmhLTHR4SlY5TTREWlBmbTdLaU9FSkxZQ19yY1NNRW1SZVdoZkU4OVJtTnBldzFvU3ljYjEyMHRRV2FCR0dWQ09LNFNqQkswTnZmWlU3aDNjbFdvRGtlaU15b2NsaWViYjlMMzNmOA?oc=5","date":"2025-07-24","type":"trial","source":"globaldata.com","summary":"Immuno-oncology: Strategic Intelligence - globaldata.com","headline":"Immuno-oncology: Strategic Intelligence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWEI3NmRIOUttU041bmNyWmJfZkFneW9HMTRGbDN4OTRkdk1RemNyWXliLVNEUkxLY2FKTktUY1hacXpXZ2ZVMzV6amdVSTRweHhibUJad3JBVFNRdG9ma2NRd3QwQ0xpM3hYSndsM2JyM09SMzRGQjVSekZaTnFsY19kQXRRVGRfX2xVanl4NmRHeVp4cS1tajNBNFI4Y2Nna2tTUncxNzJuNmxsUV9oZmJqZGhNb1k2aW1r?oc=5","date":"2024-12-12","type":"regulatory","source":"ASCO Daily News","summary":"Challenges Remain in RCC Treatment Beyond Contemporary First-Line IO Therapy: Are Second-Line Non-IO Regimens the Answer? - ASCO Daily News","headline":"Challenges Remain in RCC Treatment Beyond Contemporary First-Line IO Therapy: Are Second-Line Non-IO Regimens the Answer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQbXdENEZTb0ZkUnlxX29iTHlNdzhuZkxzQlJ3OTlCb1o0ZEJTa3kyZFhzbGpPTjJxaV9qY2JQUnpNRWh4dGIwbnlCZ2VzUWdIajhoSUJNMTJBdEt3WW1VU0FTT1BMajBZMUNHTGg1NHI2YXUyVE5WRU1qcGxoekJmTmx2aWRRX2VFN0JJY2RsczgxeTJoOUp0dEgySU1QTUFRV3UzeHFSckUtSDlpMFhTeFJBLVdMUEVoZ1dKazN4Yw?oc=5","date":"2021-04-19","type":"regulatory","source":"Fierce Pharma","summary":"Bristol Myers' Opdivo wins landmark FDA nod as first I-O therapy for front-line stomach cancer - Fierce Pharma","headline":"Bristol Myers' Opdivo wins landmark FDA nod as first I-O therapy for front-line stomach cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPZlR1U014ZHpLOURsT3ZVOVBJZ21PeTN2VlJlWDVjejdSUTFVUzdFU3REelVVeGtLWWE5UjBJbUpucWVOZjVxWGIyLTdSQ0pOMnFPTWF3ZlpibURNYnZwWlB3Wm5KVnJlemhpVV9veU9kbkVHZXNrdlV4c3FVUDVTcW9mdWVkX0hfWFRPT3FTYUFOV0VqazdlZQ?oc=5","date":"2020-05-07","type":"pipeline","source":"pharmaceutical-journal.com","summary":"Immuno-oncology agents for cancer therapy - pharmaceutical-journal.com","headline":"Immuno-oncology agents for cancer therapy - pharmaceutical","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}